About PolpharmaWe are the largest Polish manufacturer of pharmaceuticals and a leader of the Polish pharmaceutical market. We actively operate in the markets of Central and Eastern Europe, the Caucasus and Central Asia.
ResponsibilityBeing the largest Polish pharmaceutical company we want to help people to live a healthy life in a healthy world. Social responsibility is an integral part of the management strategy in our company.
CareerPolpharma's development is possible only thanks to the commitment of our employees as well as the involvement of students and graduates in various business areas.
PRICE INQUIRY No. SEMA/43/PR84503/2024 – being conducted as a market assessment study18 November 2024In connection with the implementation of the project titled “Design and development of an innovative solution – a generic drug of the GLP-1 receptor agonist… read more
PRICE INQUIRY no. NUSI/92/PR83465/2024 – being conducted as a market assessment study14 November 2024In connection with the implementation of the project titled „Development of a universal fast-response platform, based on RNA technology, ensuring the national drug and epidemiological… read more
PRICE INQUIRY no. NUSI/90/PR81538/2024 – being conducted as a market assessment study29 October 2024In connection with the implementation of the project titled „Development of a universal fast-response platform, based on RNA technology, ensuring the national drug and epidemiological… read more
PRICE INQUIRY no. NUSI/87/PR81347/2024 – being conducted as a market assessment study24 October 2024In connection with the implementation of the project titled „Development of a universal fast-response platform, based on RNA technology, ensuring the national drug and epidemiological… read more
PRICE INQUIRY no. NUSI/88/ZZ481486/2024 – being conducted as a market assessment study22 October 2024In connection with the implementation of the project titled „Development of a universal fast-response platform, based on RNA technology, ensuring the national drug and epidemiological… read more
